109669
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
司库奇尤成功治疗小儿泛发性脓疱型银屑病
Received 10 September 2024
Accepted for publication 30 December 2024
Published 16 January 2025 Volume 2025:18 Pages 105—108
DOI https://doi.org/10.2147/CCID.S493665
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Anne-Claire Fougerousse
摘要：泛发性脓疱型银屑病（GPP）是一种罕见且严重的银屑病类型，可危及生命，且通常对传统全身治疗具有耐药性。该病可由白细胞介素（IL）-36受体拮抗剂缺乏所诱发。GPP患者的治疗往往颇为棘手，且迄今为止尚未就最佳治疗方案达成共识。然而，多种已获批用于治疗斑块状银屑病的生物制剂也被用于GPP的治疗。本文报告了一例6岁的GPP男童，该患儿被误诊为急性泛发性发疹性脓疱病（AGEP），接受皮质类固醇治疗后效果不佳。但在接受司库奇尤单抗治疗后，其症状显著改善。本病例报告表明，IL-17A抑制剂作为无需联合其他全身性药物的单一治疗选择，为儿童GPP患者提供了一种有前景的治疗方案。